Published in Cancer Weekly, April 19th, 2005
In AML patients, CR "is the primary endpoint for the evaluation of induction treatment and treatment strategies," hematologists in the Netherlands explained.
"However, the choice and application of the criteria for a hematological CR can often become a subject of debate because regeneration of >5% blasts may be present at the time of response evaluation; platelet and neutrophil recovery may be incomplete and marrow cellularity can vary," noted G.E. de Greef and colleagues at the Erasmus Medical Center in Rotterdam.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.